Results 121 to 130 of about 4,340 (195)

Methylation-induced suppression of YAP/TAZ confers sensitivity to HDAC inhibitors in high-grade IDH mutant gliomas. [PDF]

JCI Insight
Sears TK, McCord M, Wang W, Steffens A, McCortney K, Chaliparambil R, Sarkaria JN, Horbinski CM.   +7 more
europepmc   +1 more source

Docking belinostat into HDAC 8 using autodock tool

Can Tho University Journal of Science, 2020
Thao, H.N., De, T.Q., Hue, B.T.B., Tuan, N.T., Bach, L.T., Quoc, N.C., Si, N.T., Toan, N.H., Quy, H.T.K.   +8 more
openaire   +2 more sources

Dual molecular therapy targeting tumor cell heterogeneity improves therapeutic efficacy in glioblastoma. [PDF]

iScience
Hirano S, Uneda A, Otani Y, Suruga Y, Imoto R, Hokama M, Umeda T, Ikemachi R, Nishigaki S, Tsuboi N, Makino K, Kemmotsu N, Kegoya Y, Matsumoto Y, Tomita Y, Shimazu Y, Ishida J, Fujii K, Wakimoto H, Tanaka S, Date I.   +20 more
europepmc   +1 more source

Polyfunctionalized <i>N</i>-Arylsulfonyl Indoles: Identification of (<i>E</i>)-<i>N</i>-Hydroxy-3-{3-[(5-(3-(piperidin-1-yl)propoxy]-1<i>H</i>-indol-1-yl)sulfonyl]phenyl}acrylamide (MTP150) for the Epigenetic-Based Therapy of Parkinson's Disease. [PDF]

Int J Mol Sci
Toledano-Pinedo M, Porro-Pérez A, Schäker-Hübner L, Diez-Iriepa D, Iriepa I, Siwek A, Wolak M, Satała G, Bojarski AJ, Doroz-Płonka A, Handzlik J, Godyń J, Dallemagne P, Rochais C, Davis A, Since M, Pérez B, Bellver-Sanchis A, Irisarri A, Pallàs M, Solana-Manrique C, López-Muñoz F, Ismaili L, Griñán-Ferré C, Paricio N, K Hansen F, Więckowska A, Marco-Contelles J.   +27 more
europepmc   +1 more source

Protocol for enhancing CRISPR-Cas9 genome editing using histone deacetylase inhibition and engineered virus-like particle delivery. [PDF]

STAR Protoc
Djamshidi M, Tanida R, Heshmatzad K, Krowicki H, Hill A, Yang Y, Riabowol K.   +6 more
europepmc   +1 more source

Protein domain movement involved in binding of belinostat and HPOB as inhibitors of histone deacetylase 6 (HDAC6): a hybrid automated-interactive docking study. [PDF]

J Comput Aided Mol Des
Iakovou G, Palmer L, Ganesan A, Kitao A, Laycock SD, Hayward S.   +5 more
europepmc   +1 more source

HDAC inhibitors as anticancer drugs: chemical diversity, clinical trials, challenges and perspectives. [PDF]

RSC Adv
Abdallah AE.
europepmc   +1 more source

Novel biologic therapies for thymic epithelial tumors

Frontiers in Oncology, 2014
YUANBIN eCHEN, Helen eGharwan, Anish eThomas   +2 more
doaj   +1 more source

From bench to bedside: combining HDAC inhibitors with standard therapies in rhabdomyosarcoma treatment. [PDF]

Front Cell Dev Biol
Macrì E, Attili M, Locatelli F, Marampon F, Pomella S.   +4 more
europepmc   +1 more source

Reversing Bladder Cancer Chemo-resistance through Blocking Cell Senescence by a Combination Therapy. [PDF]

Theranostics
He Y, Fang Z, Zhang J, Wei Q, Li Y, Duan Z, Xu G, Lin T, Xiong Q, Gong Q, Tan P, Luo K.   +11 more
europepmc   +1 more source